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Mst1 and Mst2 are key components of the Hippo tumor suppressor pathway. In this issue, Zhou et al. (2009)
reported that Mst1/2 ablation leads to hepatocellular carcinomas. Unexpectedly, Mst1/2 may activate
another kinase besides Lats1 and Lats2 to phosphorylate YAP, and the role of Mst1/2 in YAP regulation is
cell type dependent.Mst1 and Mst2 are STE20 family kinases
homologous to the Drosophila Hippo,
a foundingmember of the Hippo pathway.
Mst1/2 in association with an adaptor
protein SAV1 phosphorylates and acti-
vates Lats1 and Lats2 kinases, which
associates with another adaptor, Mob
(Figure 1A). The Hippo pathway proteins
inhibit cell proliferation and promote
apoptosis by directly phosphorylating
and inhibiting a transcription coactivator,
Yes-associated protein (YAP) (Zhao et al.,
2007), which is also a candidate human
oncogene (Overholtzer et al., 2006;
Zender et al., 2006). Genetic manipula-
tions of the Hippo pathway in Drosophila
revealed critical roles of these genes in
organ size control (Kango-Singh and
Singh, 2009). Several of the Hippo path-
way proteins are mutated in cancers and
are potential tumor suppressors. There-
fore, thispathway regulates a fundamental
aspect of normal development and plays
an important role in human cancers, so
mammalian genetic models of this
pathway are highly anticipated.
Previous genetic manipulation of the
Hippo pathway in mouse provided limited
information because of genetic redun-
dancy or early lethality. For example,Mst1
knockoutmice develop normally probably
because of redundant functions of Mst2,
although they carry some immunological
defects (Katagiri et al., 2009; Zhou et al.,
2008). The one exception is a liver-
specific Yap transgenic mice model that
showed a reversible and dramatic over-
growth of liver and the development of
hepatocellular carcinoma (HCC), confirm-
ing the role of YAP in organ size regulation
and tumorigenesis (Camargo et al., 2007;
Dong et al., 2007).In this issue, by using both germline and
liver-specific conditional Mst1/2 double
knockout mouse models, Bardeesy,
Avruch, and colleagues confirmed the
regulation of YAP phosphorylation in
mediating Mst1/2 functions (Zhou et al.,
2009). Ablation of both Mst1 and Mst2
largely abolished YAP phosphorylation in
liver, increased YAP nuclear localization
and target gene expression, and caused
liver tumorigenesis. Knockdown of YAP
reversed the transformed phenotype of
HCC-derived cells from these mice. Strik-
ingly, liver-specific Mst1/Mst2/ mice
developed enlarged liver phenotypes
similar to Yap transgenic mice and their
livers are more resistant to FAS ligand-
induced apoptosis. These in vivo experi-
ments further supported the physiological
function of Mst1/2 in YAP inhibition.
The Mst1/2 double knockout mice also
unequivocally established the role of the
Hippo pathway in tumorigenesis. Interest-
ingly, the germline Mst1/Mst2+/ mice
mainly developed HCC because of Mst2
loss of heterozygosity. This result sug-
gests that the Hippo pathway may be
particularly important in liver and is con-
sistent with previous observations that
elevated YAP is most frequently observed
in human liver cancers (Zhao et al., 2007).
Moreover, tissue-specific ablation of both
Mst1 and Mst2 in liver leads to massive
HCC with a mean latency of 10 weeks,
very similar to what is observed with
YAP overexpression. Strikingly, 70% of
human HCC samples show a markedly
reduced Mst1/2 activity as determined
by Mob phosphorylation and most of
them are also confirmed by loss of the
presumably active cleaved form of Mst1.
It is worth noting that in all but three ofCancer Cell 16,those samples with attenuated Mst1/2
activity, YAP phosphorylation is also
clearly decreased. Together with previous
observations of YAP genomic amplifica-
tion (Overholtzer et al., 2006; Zender
et al., 2006) and elevated nuclear localiza-
tion in human HCC (Dong et al., 2007;
Zhao et al., 2007), one may conclude
that YAP activation plays important roles
in human HCC, and an impaired Hippo
pathway might be a common mechanism
for YAP activation.
One unexpected finding in this report
is the cell-type-dependent function of
Mst1/2 in YAP regulation. Although
Mst1/2 are ubiquitously expressed, their
activity was shown to be differentially
regulated in different cell types. For
example, Mst1/2 could be cleaved into
a 34 kDa presumably active N-terminal
fragment in liver but not in spleen or
MEF cells (Figures 1B and 1C). Although
the caspase-dependent cleavage of
Mst1/2 is known to activate the kinase in
other contexts, this regulation has not
been examined in the Hippo pathway
nor shown to be tissue specific. It is worth
noting that the cleaved form ofMst1/2 lost
the SAV1-interacting SARAH domain.
SAV1 is required for Hippo pathway
activity in Drosophila and for Mst1 phos-
phorylation and translocation under dif-
ferentiation signal in mammalian keratino-
cytes (Lee et al., 2008). So in liver, SAV1 is
either not required for Hippo pathway
activity or functions prior to Mst1/2
cleavage. Either way, there likely exist
cell-type-specific variations of the Hippo
pathway. As shown in this report,
Mst1/2 are not required for Lats1/2 phos-
phorylation and cell density-stimulated
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Previewsin MEFs (Figure 1C). Lats1/2 are NDR
family kinases that require phosphoryla-
tion of the hydrophobic motif by upstream
kinases for activation. Therefore, a key
question is what is the upstream acti-
vating kinase of Lats1/2 in MEF cells in
response to cell contact? Potential candi-
dates are Mst3, Mst4, or YSK1, three
kinases most similar to Mst1 and Mst2
with identical residues in their substrate-
binding pockets. It is also possible that
a totally unrelated kinase phosphorylates
Lats1/2.
The possible existence of a YAP kinase
other than Lats1/2 downstream of Mst1/2
in liver is the other interesting finding of
this work (Figure 1B). Two pieces of
evidence support this prediction: first,
Mst1/2 ablation in liver reduced YAP
phosphorylation but had little effect on
Lats1/2 phosphorylation; second, frac-
tionation of liver lysates showed Mst1/2-
regulated YAP kinase activity distinct
from Lats1/2, whereas Lats1/2 activity is
unresponsive to Mst1/2 deficiency. Note-
worthy, the decrease of NDR1/2 phos-
phorylation in Mst1/2-deficient liver is
consistent with the possibility of them
being the elusive kinases. It should also
be noted that in the kinase assaywith frac-
tionated liver lysates, distribution of the
phosphorylated endogenous YAP strictly
correlated with Lats1, suggesting that
Lats1 may form a complex with endoge-
nousYAP. To unequivocally clarify the role
of Lats1/2 or other kinases in YAP phos-
phorylation, mouse models with Lats1
and Lats2 double deletion are needed.
This report confirmed the inhibition of
YAP by Mst1/2 as an important mecha-
nism in tumor suppression, especially in
HCC. And as of many other interesting
studies, more questions have been raised
than been answered. To what extent
could the Hippo pathway differ in different
cell types? In MEF cells, what is the
kinase in response to cell contact signal
upstream of Lats1/2? What is the YAP
kinase acting downstream of Mst1/2 in
liver? And what are the mechanisms of
Mst1/2 inactivation and YAP dysregula-
tion in human cancers? Answers to these
questions will significantly advance our
understanding of the Hippo pathway in
normal organ size control and patholog-
ical tumor development.
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Figure 1. Cell Type Dependent Variation of the Hippo Pathway
(A) A generally accepted paradigm of the Hippo pathway.
(B) Hippo pathway in liver and cultured hepatocytes. CleavedMst1/2 activate an unknown kinase of YAP, and Lats1/2 may phosphorylate YAP once activated by
a kinase distinct from Mst1/2.
(C) Hippo pathway inMEF cells. High cell density activates an elusive kinase to activate Lats1/2 and stimulate phosphorylation of YAP.Mst1/2 are not required for
YAP phosphorylation in MEFs.364 Cancer Cell 16, November 3, 2009 ª2009 Elsevier Inc.
